middle.news
Syntara Advances Myelofibrosis and Scar Treatments Amid Strong Cash Position
5:13am on Monday 2nd of June, 2025 AEST
•
Healthcare
Read Story
Syntara Advances Myelofibrosis and Scar Treatments Amid Strong Cash Position
5:13am on Monday 2nd of June, 2025 AEST
Key Points
SNT-5505 myelofibrosis interim data accepted for EHA 2025 presentation
Phase 1a/b trial launched for next-gen topical anti-fibrotic SNT-9465 targeting hypertrophic and keloid scars
Imaging from SOLARIA2 trial shows structural normalization of scars with SNT-6302
Strong cash balance of $18 million supports ongoing clinical programs
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Syntara (ASX:SNT)
OPEN ARTICLE